Eximore is bringing to the ophthalmic market a novel punctum plug where the plug itself is made from active drug. The company’s initial development is a non-invasive, novel sustained-release delivery system to create a “pack and release” that can effectively treat eye diseases such as glaucoma and dry eye. Eximore is commencing its initial human study to pack and release latanoprost to treat glaucoma, while concurrently progressing its research on additional indications such as dry eye.
CEO: Eyal Sheetrit